20 results on '"Hogan, Catherine A"'
Search Results
2. SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19.
- Author
-
Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, Röltgen K, Stevens BA, Yamamoto F, Sahoo MK, Zehnder J, Boyd SD, and Pinsky BA
- Subjects
- Electrochemical Techniques, Hospitalization, Humans, Immunoassay, Luminescent Measurements, Nucleocapsid, Phosphoproteins blood, SARS-CoV-2, Sensitivity and Specificity, Antigens, Viral blood, COVID-19 diagnosis, COVID-19 Testing methods, Coronavirus Nucleocapsid Proteins blood
- Abstract
Background: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity., Methods: We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity., Results: Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity., Conclusions: SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization., (© American Association for Clinical Chemistry 2021.)
- Published
- 2021
- Full Text
- View/download PDF
3. Ultra-sensitive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples.
- Author
-
Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, Zehnder J, Sahoo MK, and Pinsky BA
- Subjects
- Humans, Immunologic Tests, Prospective Studies, Retrospective Studies, COVID-19, SARS-CoV-2
- Abstract
An ultra-sensitive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen assay (S-PLEX, MesoScale Diagnostics) was evaluated in 250 retrospective and 200 prospective upper respiratory specimens. In samples with cycle threshold <35, there was 95%-98% positive and 93%-96% negative percent agreement with reverse transcription-polymerase chain reaction. S-PLEX may provide a high-throughput alternative to nucleic acid-based testing for coronavirus disease 2019 (COVID-19) diagnosis., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
4. Evaluation of the clinical and analytical performance of the Seegene allplex™ SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI).
- Author
-
Caza M, Hogan CA, Jassem A, Prystajecky N, Hadzic A, and Wilmer A
- Subjects
- Humans, RNA, Viral, Reproducibility of Results, COVID-19, SARS-CoV-2
- Abstract
Background: High-throughput assays for the detection of SARS-CoV-2 variants of concern (VOC) and interest (VOI) are a diagnostic alternative when whole genome sequencing (WGS) is unavailable or limited., Objective: This study evaluated the clinical and analytical performance of the Seegene Allplex™ SARS-CoV-2 Variants I assay, which detects the HV69/70 deletion, N501Y and E484K mutations of the S gene., Methods: Genotyping was evaluated on -871 SARS-CoV-2 RNA positive specimens, 408 nasopharyngeal (NP) swabs and 463 saline gargle (SG) specimens, with WGS used as the reference standard. Analytical performance was assessed including stability, reproducibility, limit of detection (LOD), cross-reactivity and interference with various respiratory microorganisms., Results: The clinical study revealed sensitivity of 100% (95% CI 99.27%-100%) and specificity of 100% (95% CI 98.99%-100%) for HV69/70 deletion, sensitivity of 100% (95% CI 99.55%-100%) and specificity of 100% (95% CI 93.73% - 100%) for N501Y, and sensitivity of 100% (95% CI 98.94% - 100%) and specificity of 98.10% (95% CI 96.53% - 99.08%) for E484K mutation. The E484Q mutation was detected in 10 specimens of the Kappa variant (B.1.627.1). Analytical performance demonstrated stability and reproducibility over 7 days, and LOD was calculated at 698 cp/mL for NP swab specimens, and 968 cp/mL for SG specimens. No interference or cross-reactivity with other microorganisms was noted., Conclusion: The Allplex™ SARS-CoV-2 Variants I assay is acceptable for clinical use for the detection of variant of concern and variant of interest., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
5. Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021.
- Author
-
Hogan CA, Jassem AN, Sbihi H, Joffres Y, Tyson JR, Noftall K, Taylor M, Lee T, Fjell C, Wilmer A, Galbraith J, Romney MG, Henry B, Krajden M, Galanis E, Prystajecky N, and Hoang LMN
- Subjects
- British Columbia epidemiology, Humans, Real-Time Polymerase Chain Reaction, COVID-19 epidemiology, COVID-19 virology, SARS-CoV-2
- Abstract
Several severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) emerged in late 2020; lineage B.1.1.7 initially dominated globally. However, lineages B.1.351 and P.1 represent potentially greater risk for transmission and immune escape. In British Columbia, Canada, B.1.1.7 and B.1.351 were first identified in December 2020 and P.1 in February 2021. We combined quantitative PCR and whole-genome sequencing to assess relative contribution of VOCs in nearly 67,000 infections during the first 16 weeks of 2021 in British Columbia. B.1.1.7 accounted for <10% of screened or sequenced specimens early on, increasing to >50% by week 8. P.1 accounted for <10% until week 10, increased rapidly to peak at week 12, and by week 13 codominated within 10% of rates of B.1.1.7. B.1.351 was a minority throughout. This rapid expansion of P.1 but suppression of B.1.351 expands our understanding of population-level VOC patterns and might provide clues to fitness determinants for emerging VOCs.
- Published
- 2021
- Full Text
- View/download PDF
6. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic.
- Author
-
Rosser JI, Röltgen K, Dymock M, Shepard J, Martin A, Hogan CA, Blomkalns A, Mathew R, Parsonnet J, Pinsky BA, Maldonado YA, Boyd SD, Chang SI, and Holubar M
- Subjects
- California epidemiology, Delivery of Health Care, Humans, SARS-CoV-2, Seroepidemiologic Studies, COVID-19, Pandemics
- Abstract
Objective: We assessed the magnitude of unidentified coronavirus disease 2019 (COVID-19) in our healthcare personnel (HCP) early in the COVID-19 pandemic, and we evaluated risk factors for infection to identify areas for improvement in infection control practice in a northern California academic medical center., Methods: We reviewed anti-severe acute respiratory coronavirus virus 2 (SARS-CoV-2) receptor-binding domain (RBD) IgG serologic test results and self-reported risk factors for seropositivity among 10,449 asymptomatic HCP who underwent voluntary serology testing between April 20 and May 20, 2020., Results: In total, 136 employees (1.3%) tested positive for SARS-CoV-2 IgG. This included 41 individuals (30.1%) who had previously tested positive for SARS-CoV-2 by nasopharyngeal reverse-transcription polymerase chain reaction (RT-PCR) between March 13 and April 16, 2020. In multivariable analysis, employees of Hispanic ethnicity (odds ratio [OR], 2.01; 95% confidence interval [CI], 1.22-3.46) and those working in environmental services, food services, or patient transport (OR, 4.81; 95% CI, 2.08-10.30) were at increased risk for seropositivity compared to other groups. Employees reporting a household contact with COVID-19 were also at higher risk for seropositivity (OR, 3.25; 95% CI, 1.47-6.44), but those with a work, exposure alone were not (OR, 1.27; 95% CI, 0.58-2.47). Importantly, one-third of seropositive individuals reported no prior symptoms, no suspected exposures, and no prior positive RT-PCR test., Conclusion: In this study, SARS-CoV-2 seropositivity among HCP early in the northern California epidemic appeared to be quite low and was more likely attributable to community rather than occupational exposure.
- Published
- 2021
- Full Text
- View/download PDF
7. Carving Out a Niche for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Plasma RNA Testing.
- Author
-
Pinsky BA and Hogan CA
- Subjects
- Hospitalization, Humans, Intensive Care Units, RNA, Viral genetics, COVID-19, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
8. Plasma as an alternative COVID-19 diagnostic specimen in a hospitalized patient negative for SARS-CoV-2 by nasopharyngeal swab.
- Author
-
Lawrence L, Stevens BA, Sahoo MK, Huang C, Yamamoto F, Röltgen K, Wirz O, Zehnder J, Shi RZ, Boyd SD, Schoolnik G, Pinsky BA, and Hogan CA
- Subjects
- Adult, COVID-19 Nucleic Acid Testing, Humans, Male, Nasopharynx virology, RNA, Viral genetics, Specimen Handling, COVID-19 diagnosis, Plasma virology, SARS-CoV-2 isolation & purification
- Abstract
We present the case of an inpatient with pneumonia and repeatedly negative nasopharyngeal SARS-CoV-2 testing. In such challenging cases, alternative diagnostic options include lower respiratory tract and plasma SARS-CoV-2 RNA testing, of which the latter may be particularly useful where bronchoscopy is deferred due to clinical factors or transmission risk., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
9. High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease.
- Author
-
Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, Yamamoto F, Murugesan K, Kurzer J, Zehnder J, and Pinsky BA
- Subjects
- Cross-Sectional Studies, Hospitalization, Humans, Middle Aged, RNA, Viral, COVID-19, SARS-CoV-2
- Abstract
Background: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in blood, also known as RNAemia, has been reported, but its prognostic implications are poorly understood. This study aimed to determine the frequency of SARS-CoV-2 RNA in plasma and its association with coronavirus disease 2019 (COVID-19) clinical severity., Methods: An analytical cross-sectional study was performed in a single-center tertiary care institution and included consecutive inpatients and outpatients with confirmed COVID-19. The prevalence of SARS CoV-2 RNAemia and the strength of its association with clinical severity variables were examined and included intensive care unit (ICU) admission, invasive mechanical ventilation, and 30-day all-cause mortality., Results: Paired nasopharyngeal and plasma samples were included from 85 patients. The median age was 55 years, and individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma (63 vs 50 years; P = .04). Comorbidities were frequent including obesity (37.6%), hypertension (30.6%), and diabetes mellitus (22.4%). RNAemia was detected in 28/85 (32.9%) of patients, including 22/28 (78.6%) who required hospitalization. In models adjusted for age, RNAemia was detected more frequently in individuals who developed severe disease including ICU admission (32.1 vs 14.0%; P = .04) and invasive mechanical ventilation (21.4% vs 3.5%; P = .02). All 4 deaths occurred in individuals with detectable RNAemia. An additional 121 plasma samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was detected for a maximum duration of 10 days., Conclusions: This study demonstrated a high proportion of SARS-CoV-2 RNAemia, and an association between RNAemia and clinical severity suggesting the potential utility of plasma viral testing as a prognostic indicator for COVID-19., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
10. Combined SARS-CoV-2 nucleic acid amplification testing and respiratory virus panel RT-PCR on the Hologic Panther Fusion system.
- Author
-
Stevens BA, Hogan CA, Mfuh KO, Khan G, Sahoo MK, Huang C, Garamani N, Zehnder J, Kurzer J, and Pinsky BA
- Subjects
- Diagnostic Tests, Routine, Humans, Influenza, Human diagnosis, Retrospective Studies, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Nucleic Acid Testing methods, Nasopharynx virology, RNA, Viral isolation & purification, SARS-CoV-2 isolation & purification
- Abstract
Background: Significant overlap exists between the symptoms of SARS-CoV-2 and other respiratory viruses. This poses a serious challenge to clinical diagnosis, laboratory testing, and infection control programs., Objectives: To evaluate the performance of the Hologic Panther Fusion Respiratory Assays (RA) compared to the GenMark ePlex Respiratory Pathogen Panel (RPP) and to assess the ability of the Panther Fusion to perform parallel testing of SARS-CoV-2 and other respiratory viruses from a single sample., Study Design: A diagnostic comparison study was carried out using 375 clinical nasopharyngeal specimens. Assay performance was assessed by overall, positive, and negative percent agreement and Cohen's kappa coefficient., Results: Overall agreement between the Fusion RA and ePlex RPP was 97.3 % (95 % CI 96.3-98.0), positive percent agreement was 97.2 % (95 % CI 93.0-99.2), negative percent agreement was 97.3 % (95 % CI 96.3-98.0), and the kappa coefficient was 0.85 (95 % CI 0.81-0.89). Forty additional viruses in 30 specimens were detected by Fusion that were not detected by ePlex. The maximum specimen throughput for parallel testing of the Fusion Respiratory Assays with SARS-CoV-2 was 275 samples in 20.7 h for Fusion SARS-CoV-2 and 350 samples in 20.0 h for Aptima Transcription Mediated Amplification SARS-CoV-2., Conclusion: Fusion RA demonstrated substantial agreement compared to the ePlex RPP. However, the Fusion detected respiratory viruses not identified by ePlex, consistent with higher clinical sensitivity. Workflows for parallel testing of respiratory pathogens and SARS-CoV-2 demonstrate that the Panther Fusion instrument provides a flexible, moderate to high throughput testing option for pandemic and seasonal respiratory viruses., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
11. Strand-Specific Reverse Transcription PCR for Detection of Replicating SARS-CoV-2.
- Author
-
Hogan CA, Huang C, Sahoo MK, Wang H, Jiang B, Sibai M, Holubar M, Mathew R, Zehnder J, and Pinsky BA
- Subjects
- Adult, COVID-19 transmission, COVID-19 Nucleic Acid Testing methods, Clinical Decision-Making, Disease Transmission, Infectious, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, RNA, Viral physiology, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, SARS-CoV-2 physiology, COVID-19 diagnosis, COVID-19 Nucleic Acid Testing standards, RNA, Viral analysis, SARS-CoV-2 genetics, Virus Replication genetics
- Abstract
We developed an assay that detects minus-strand RNA as a surrogate for actively replicating severe acute respiratory syndrome coronavirus 2. We detected minus-strand RNA in 41 persons with coronavirus disease up to 30 days after symptom onset. This assay might inform clinical decision-making about patient infectiousness.
- Published
- 2021
- Full Text
- View/download PDF
12. Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative Patients.
- Author
-
Long DR, Gombar S, Hogan CA, Greninger AL, O'Reilly-Shah V, Bryson-Cahn C, Stevens B, Rustagi A, Jerome KR, Kong CS, Zehnder J, Shah NH, Weiss NS, Pinsky BA, and Sunshine JE
- Subjects
- COVID-19 Testing, Humans, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, COVID-19, SARS-CoV-2
- Abstract
Using data for 20 912 patients from 2 large academic health systems, we analyzed the frequency of severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction test discordance among individuals initially testing negative by nasopharyngeal swab who were retested on clinical grounds within 7 days. The frequency of subsequent positivity within this window was 3.5% and was similar across institutions., (Published by Oxford University Press for the Infectious Diseases Society of America 2020.)
- Published
- 2021
- Full Text
- View/download PDF
13. Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens.
- Author
-
Wang H, Hogan CA, Miller JA, Sahoo MK, Huang C, Mfuh KO, Sibai M, Zehnder J, Hickey B, Sinnott-Armstrong N, and Pinsky BA
- Subjects
- COVID-19 virology, Clinical Laboratory Techniques methods, False Negative Reactions, Humans, Molecular Diagnostic Techniques methods, Nucleic Acid Amplification Techniques standards, Prospective Studies, SARS-CoV-2 genetics, Sensitivity and Specificity, Specimen Handling, Stochastic Processes, COVID-19 diagnosis, COVID-19 Testing methods, Nucleic Acid Amplification Techniques methods, SARS-CoV-2 isolation & purification
- Abstract
Pooled nucleic acid amplification tests for severe acute respiratory syndrome coronavirus 2 could increase availability of testing at decreased cost. However, the effect of dilution on analytical sensitivity through sample pooling has not been well characterized. We tested 1,648 prospectively pooled specimens by using 3 nucleic acid amplification tests for severe acute respiratory syndrome coronavirus 2: a laboratory-developed real-time reverse transcription PCR targeting the envelope gene, and 2 commercially available Panther System assays targeting open reading frame 1ab. Positive percent agreement (PPA) of pooled versus individual testing ranged from 71.7% to 82.6% for pools of 8 and from 82.9% to 100.0% for pools of 4. We developed and validated an independent stochastic simulation model to estimate effects of dilution on PPA and efficiency of a 2-stage pooled real-time reverse transcription PCR testing algorithm. PPA was dependent on the proportion of tests with positive results, cycle threshold distribution, and assay limit of detection.
- Published
- 2021
- Full Text
- View/download PDF
14. Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2.
- Author
-
Hogan CA, Gombar S, Wang H, Röltgen K, Shi RZ, Holubar M, Chang SI, Lee GM, Boyd SD, Zehnder J, and Pinsky BA
- Subjects
- Adult, COVID-19 Testing, Female, Humans, Male, Middle Aged, Prevalence, Asymptomatic Infections, COVID-19 diagnosis, Health Personnel, SARS-CoV-2
- Abstract
Large-scale, 1-time testing of >12,000 asymptomatic healthcare personnel in California, USA, during April-June 2020 showed that prevalence of severe acute respiratory syndrome coronavirus 2 was low (<1%). Testing might identify asymptomatic and presymptomatic persons, including some with high viral burden, enabling prompt implementation of measures to limit nosocomial spread.
- Published
- 2021
- Full Text
- View/download PDF
15. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
- Author
-
Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, and Boyd SD
- Subjects
- Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme 2 blood, Angiotensin-Converting Enzyme 2 genetics, Angiotensin-Converting Enzyme 2 immunology, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, COVID-19 blood, COVID-19 genetics, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Real-Time Polymerase Chain Reaction, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus blood, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus immunology, Antibodies, Viral immunology, COVID-19 immunology, Severity of Illness Index
- Abstract
SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the serological response may affect clinical outcomes of COVID-19 patients. We analyzed 983 longitudinal plasma samples from 79 hospitalized COVID-19 patients and 175 SARS-CoV-2-infected outpatients and asymptomatic individuals. Within this cohort, 25 patients died of their illness. Higher ratios of IgG antibodies targeting S1 or RBD domains of spike compared to nucleocapsid antigen were seen in outpatients who had mild illness versus severely ill patients. Plasma antibody increases correlated with decreases in viral RNAemia, but antibody responses in acute illness were insufficient to predict inpatient outcomes. Pseudovirus neutralization assays and a scalable ELISA measuring antibodies blocking RBD-ACE2 interaction were well correlated with patient IgG titers to RBD. Outpatient and asymptomatic individuals' SARS-CoV-2 antibodies, including IgG, progressively decreased during observation up to five months post-infection., (Copyright © 2020, American Association for the Advancement of Science.)
- Published
- 2020
- Full Text
- View/download PDF
16. Targeted plasma metabolomics combined with machine learning for the diagnosis of severe acute respiratory syndrome virus type 2.
- Author
-
Le, Anthony T., Manhong Wu, Khan, Afraz, Phillips, Nicholas, Rajpurkar, Pranav, Garland, Megan, Magid, Kayla, Sibai, Mamdouh, ChunHong Huang, Sahoo, Malaya K., Bowen, Raffick, Cowan, Tina M., Pinsky, Benjamin A., and Hogan, Catherine A.
- Abstract
Introduction: The routine clinical diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely restricted to real-time reverse transcription quantitative PCR (RT-qPCR), and tests that detect SARS-CoV-2 nucleocapsid antigen. Given the diagnostic delay and suboptimal sensitivity associated with these respective methods, alternative diagnostic strategies are needed for acute infection. Methods: We studied the use of a clinically validated liquid chromatography triple quadrupole method (LC/MS–MS) for detection of amino acids from plasma specimens. We applied machine learning models to distinguish between SARS-CoV-2-positive and negative samples and analyzed amino acid feature importance. Results: A total of 200 samples were tested, including 70 from individuals with COVID-19, and 130 from negative controls. The top performing model overall allowed discrimination between SARS-CoV-2-positive and negative control samples with an area under the receiver operating characteristic curve (AUC) of 0.96 (95%CI 0.91, 1.00), overall sensitivity of 0.99 (95%CI 0.92, 1.00), and specificity of 0.92 (95%CI 0.85, 0.95). Discussion: This approach holds potential as an alternative to existing methods for the rapid and accurate diagnosis of acute SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2.
- Author
-
Hogan, Catherine A., Sahoo, Malaya K., and Pinsky, Benjamin A.
- Subjects
- *
INFECTIOUS disease transmission , *COVID-19 , *BRONCHOALVEOLAR lavage , *INVASIVE diagnosis , *CORONAVIRUS diseases , *CLINICAL pathology , *VIRAL pneumonia , *RETROSPECTIVE studies , *MEDICAL screening , *TRANSFERASES , *EPIDEMICS - Abstract
This study describes findings of novel coronavirus testing on pooled nasopharyngeal and bronchoalveolar lavage samples taken from patients who had negative results by routine respiratory virus testing to see if pooling samples could increase testing throughput and efficiency and facilitate early detection of community COVID-19 transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Retrospective Screening for SARS-CoV-2 RNA in California, USA, Late 2019.
- Author
-
Hogan, Catherine A., Garamani, Natasha, Sahoo, Malaya K., ChunHong Huang, Zehnder, James, Pinsky, Benjamin A., and Huang, ChunHong
- Abstract
To investigate the possibility of earlier cases of severe acute respiratory syndrome coronavirus 2 infection than previously recognized, we retrospectively tested pooled samples from 1,700 persons with respiratory signs/symptoms seen at Stanford Health Care, Palo Alto, California, USA, during the last 2 months of 2019. We found no evidence of earlier infection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19.
- Author
-
Gombar, Saurabh, Chang, Marcello, Hogan, Catherine A., Zehnder, James, Boyd, Scott, Pinsky, Benjamin A., and Shah, Nigam H.
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *UNIVERSAL precautions (Health) , *SYMPTOMS , *VIRAL shedding , *ACADEMIC medical centers , *MEDICAL centers - Abstract
Current guidelines for returning health care workers (HCW) to service after a positive SARS-CoV-2 RT-PCR test and ceasing of transmission precautions for patients is based on two general strategies. A test-based strategy that requires negative respiratory RT-PCR tests obtained after the resolution of symptoms. Alternatively, due to the limited availability of testing, many sites employ a symptom-based strategy that recommends excluding HCW from the workforce and keeping patients on contact precautions until a fixed period of time has elapsed from symptom recovery. The underlying assumption of the symptom-based strategy is that waiting for a fixed period of time is a surrogate for negative RT-PCR testing, which itself is a surrogate for the absence of shedding infectious virus. To better understand the appropriate length of symptom based return to work and contact precaution strategies. We performed an observational analysis of 150 patients and HCW that transitioned from RT-PCR SARS-CoV-2 positive to negative over the course of 2 months at a US academic medical center. We found that the average time to transition from RT-PCR positive to negative was 24 days after symptom onset and 10 % remained positive even 33 days after symptom onset. No difference was seen in HCW and patients. These findings suggest until definitive evidence of the length of infective viral shedding is obtained that the fixed length of time before returning to work or ceasing contract precautions be revised to over one-month. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2.
- Author
-
Bulterys, Philip L., Garamani, Natasha, Stevens, Bryan, Sahoo, Malaya K., Huang, ChunHong, Hogan, Catherine A., Zehnder, James, and Pinsky, Benjamin A.
- Subjects
- *
NUCLEIC acid amplification techniques , *GENE amplification , *SARS-CoV-2 , *COVID-19 , *GENE targeting - Abstract
• Four nucleic acid amplification tests for SARS-CoV-2 RNA demonstrated comparable performance using clinical specimens. • A limited number of discrepancies were observed in specimens with low viral loads. • The isothermal amplification assay was slightly less sensitive but was one hour faster than the other methods. • Assay selection requires consideration of test performance, instrument/reagent availability, turnaround and throughput. Numerous nucleic acid amplification tests, including real-time, reverse transcription PCR (rRT-PCR) and isothermal amplification methods, have been developed to detect SARS-CoV-2 RNA, including many that have received emergency use authorization (EUA). There is a need to assess their test performance relative to one another. The aim of this study was to compare the test performance of a high complexity laboratory-developed rRT-PCR EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene with other tests: the Atila isothermal amplification assay targeting the nucleocapsid (N) gene and open reading frame 1ab (ORF1ab), the Altona E and spike (S) multiplex, real-time RT-PCR, and the US Centers for Disease Control and Prevention (CDC) N1 and N2 rRT-PCRs. A diagnostic comparison study was performed by testing nasopharyngeal samples from persons under investigation for coronavirus disease 2019 (COVID-19). Assay performance was assessed by percent agreement and Cohen's kappa coefficient. Positive percent agreement with the SHC EUA reference assay was 82.8 % (95 % confidence interval (CI) 65.0 to 92.9) for Atila, 86.7 % (95 % CI 69.7 to 95.3) for the Altona E and S targets, and 86.7 % (95 % CI 69.7 to 95.3) and 90.0 % (95 % CI 73.6 to 97.3), for the CDC N1 and N2 targets, respectively. All assays demonstrated 100 % negative percent agreement. Kappa coefficients ranged from 0.86 to 0.92, indicating excellent agreement. Performance was comparable among the SARS-CoV-2 nucleic acid amplification methods tested, with a limited number of discrepancies observed in specimens with low viral loads. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.